# US 2013/0344509 A1 · Anti-human trop-2 antibody having an antitumor activity in vivo

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0344509 A1
- Document ID: US20130344509A1
- Status: Published application
- Kind: A1
- Application number: 13/682,319
- Filed: 2012-11-20
- Published: 2013-12-26
- Earliest claimed: 2011-11-22
- Assignees: Livtech, Inc.
- Applicants: LivTech, Inc.
- Inventors: Koji NAKAMURA; Kentaro OKAMURA; Maki TAMURA; Hiroyuki YANAI; Toru KANKE; Naoya TSURUSHITA; Shankar KUMAR
- Web page: https://patentgrep.com/patent/US20130344509A1

## CPC

- C07K 16/3053: {Skin, nerves, brain}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07K 16/30: from tumour cells
- C07K 16/3023: {Lung}
- C07K 16/303: {Liver or Pancreas}
- C07K 16/3038: {Kidney, bladder}
- C07K 16/3046: {Stomach, Intestines}
- C07K 16/3069: {Reproductive system, e.g. ovaria, uterus, testes, prostate}
- C07K 16/3076: {against structure-related tumour-associated moieties}
- G01N 33/57525: of the liver or pancreas
- G01N 33/57585: {involving compounds identifiable in body fluids}
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides: an antibody which specifically reacts with hTROP-2 and has anti-tumor activity in vivo (particularly, a humanized antibody); a hybridoma which produces the aforementioned antibody; a conjugate of the aforementioned antibody and a drug; a pharmaceutical composition for diagnosing or treating a tumor; a method for detecting a tumor; and a kit for detecting or diagnosing a tumor.

## Claims

### Claim 1

An antibody against human TROP-2 in which an H chain V region of the antibody consists of the amino acid sequence shown in SEQ ID NO: 92 or 98, and an L chain V region of the antibody consists of the amino acid sequence shown in SEQ ID NO: 93.

### Claim 2 (depends on 1)

The antibody according to claim 1, wherein the amino acid sequences of CDR 1 to 3 of the H chain V region of the antibody are shown in SEQ ID NOS: 36 to 38, respectively, and/or the amino acid sequences of CDR 1 to 3 of the L chain V region of the antibody are shown in SEQ ID NOS: 41 to 43, respectively.

### Claim 3

An antibody against human TROP-2 in which an H chain V region of the antibody consists of the amino acid sequence shown in SEQ ID NO: 94 or 95, and an L chain V region of the antibody consists of the amino acid sequence shown in SEQ ID NO: 96.

### Claim 4 (depends on 3)

The antibody according to claim 3, wherein the amino acid sequences of CDR 1 to 3 of the H chain V region of the antibody are shown in SEQ ID NOS: 66 to 68, respectively, and/or the amino acid sequences of CDR 1 to 3 of the L chain V region of the antibody are shown in SEQ ID NOS: 71 to 73, respectively.

### Claim 5 (depends on 1)

The antibody according to claim 1, which is a humanized antibody.

### Claim 6 (depends on 1)

The antibody according to claim 1, which has anti-tumor activity in vivo.

### Claim 7 (depends on 1)

The antibody according to claim 1, which exhibits 50% or more of tumor growth inhibitory activity at a dosage of 5 to 20 mg/kg body weight.

### Claim 8 (depends on 7)

The antibody according to claim 7, wherein the frequency of administration for exhibiting the tumor growth inhibitory activity is at most once a week.

### Claim 9 (depends on 1)

The antibody according to claim 1, which exhibits 50% or more of the tumor growth inhibitory activity by a single administration of the antibody at a dosage of 10 mg/kg body weight.

### Claim 10 (depends on 1)

The antibody according to claim 1, which has anti-tumor activity on two or more types of human tumor cell lines.

### Claim 11 (depends on 1)

The antibody according to claim 1, wherein the dissociation constant (Kd value) is 1.0×10−10 M or less.

### Claim 12 (depends on 1)

The antibody according to claim 1, which is a monoclonal antibody.

### Claim at position 13

13-15. (canceled)

### Claim 16 (depends on 10)

The antibody according to claim 10, wherein the tumor cell lines are at least two types selected from the group consisting of a human pancreatic cancer cell line PK-59, a human pancreatic cancer cell line BxPC-3, a human pancreatic cancer cell line KP-3L, a human pancreatic cancer cell line KP-2, a human pancreatic cancer cell line PK-1, a human pancreatic cancer cell line PK-45H, a human pancreatic cancer cell line PK-45P, a human pancreatic cancer cell line TCC-PAN2, a human pancreatic cancer cell line SUIT-2, a human colon cancer cell line CACO-2, a human colon cancer cell line SW480, a human colon cancer cell line DLD-1, a human colon cancer cell line HCT 116, a human breast cancer cell line JIMT-1, a human breast cancer cell line HCC 1143, a human breast cancer cell line MCF-7, a human breast cancer cell line MDA-MB-468, a human prostate cancer cell line DU145, a human prostate cancer cell line PC-3, a human ovarian cancer cell line SK-OV-3, a human lung cancer cell line Calu-3 and a human bile duct cancer cell line TFK-1.

### Claim 17 (depends on 10)

The antibody according to claim 10, wherein the tumor cell lines are at least two types selected from the group consisting of a human pancreatic cancer cell line PK-59, a human pancreatic cancer cell line BxPC-3, a human colon cancer cell line SW480, a human lung cancer cell line Calu-3, a human breast cancer cell line MDA-MB-468 and a human ovarian cancer cell line SK-OV-3.

### Claim 18 (depends on 1)

An antibody fragment derived from the antibody according to claim 1.

### Claim at position 17

19-20. (canceled)

### Claim 21 (depends on 1)

An antibody-drug conjugate, which comprises the antibody according to claim 1 and a substance having anti-tumor activity and/or cell-killing activity.

### Claim 22 (depends on 18)

An antibody fragment-drug conjugate, which comprises the antibody fragment according to claim 18 and a substance having anti-tumor activity and/or cell-killing activity.

### Claim at position 20

23-25. (canceled)

### Claim 26 (depends on 1)

A pharmaceutical composition, which comprises the antibody according to claim 1.

### Claim 27 (depends on 26)

The composition according to claim 26, which is used in the treatment of tumor.

### Claim 28 (depends on 27)

The composition according to claim 27, which does not cause weight reduction as a side effect.

### Claim 29 (depends on 26)

The composition according to claim 26, which is used in the diagnosis of tumor.

### Claim at position 25

30-31. (canceled)

### Claim 32 (depends on 1)

A tumor therapeutic agent, which comprises the antibody according to claim 1.

### Claim at position 27

33-34. (canceled)

### Claim 35 (depends on 1)

A tumor diagnostic agent, which comprises the antibody according to claim 1.

### Claim 36

(canceled)

### Claim 37 (depends on 1)

A method for detecting a tumor, which comprises: allowing the antibody according to claim 1 to react with a sample collected from a living body; and then detecting a signal(s) of the reacted antibody.

### Claim 38

(canceled)

### Claim 39 (depends on 1)

A kit for treating, diagnosing or detecting a tumor, which comprises the antibody according to claim 1.

### Claim 40

(canceled)

### Claim 41 (depends on 1)

A polynucleotide encoding the antibody according to claim 1.

### Claim 42

(canceled)

### Claim 43 (depends on 41)

A recombinant vector comprising the polynucleotide according to claim 41.

### Claim 44 (depends on 43)

A transformant comprising the recombinant vector according to claim 43.

### Claim 45 (depends on 3)

The antibody according to claim 3, which is a humanized antibody.

### Claim 46 (depends on 3)

The antibody according to claim 3, which has anti-tumor activity in vivo.

### Claim 47 (depends on 3)

The antibody according to claim 3, which exhibits 50% or more of tumor growth inhibitory activity at a dosage of 5 to 20 mg/kg body weight.

### Claim 48 (depends on 47)

The antibody according to claim 47, wherein the frequency of administration for exhibiting the tumor growth inhibitory activity is at most once a week.

### Claim 49 (depends on 3)

The antibody according to claim 3, which exhibits 50% or more of the tumor growth inhibitory activity by a single administration of the antibody at a dosage of 10 mg/kg body weight.

### Claim 50 (depends on 3)

The antibody according to claim 3, which has anti-tumor activity on two or more types of human tumor cell lines.

### Claim 51 (depends on 3)

The antibody according to claim 3, wherein the dissociation constant (Kd value) is 1.0×10−10 M or less.

### Claim 52 (depends on 3)

The antibody according to claim 3, which is a monoclonal antibody.

### Claim 53 (depends on 50)

The antibody according to claim 50, wherein the tumor cell lines are at least two types selected from the group consisting of a human pancreatic cancer cell line PK-59, a human pancreatic cancer cell line BxPC-3, a human pancreatic cancer cell line KP-3L, a human pancreatic cancer cell line KP-2, a human pancreatic cancer cell line PK-1, a human pancreatic cancer cell line PK-4511, a human pancreatic cancer cell line PK-45P, a human pancreatic cancer cell line TCC-PAN2, a human pancreatic cancer cell line SUIT-2, a human colon cancer cell line CACO-2, a human colon cancer cell line SW480, a human colon cancer cell line DLD-1, a human colon cancer cell line HCT 116, a human breast cancer cell line JIMT-1, a human breast cancer cell line HCC 1143, a human breast cancer cell line MCF-7, a human breast cancer cell line MDA-MB-468, a human prostate cancer cell line DU145, a human prostate cancer cell line PC-3, a human ovarian cancer cell line SK-OV-3, a human lung cancer cell line Calu-3 and a human bile duct cancer cell line TFK-1.

### Claim 54 (depends on 50)

The antibody according to claim 50, wherein the tumor cell lines are at least two types selected from the group consisting of a human pancreatic cancer cell line PK-59, a human pancreatic cancer cell line BxPC-3, a human colon cancer cell line SW480, a human lung cancer cell line Calu-3, a human breast cancer cell line MDA-MB-468 and a human ovarian cancer cell line SK-OV-3.

### Claim 55 (depends on 3)

An antibody fragment derived from the antibody according to claim 3.

### Claim 56 (depends on 3)

An antibody-drug conjugate, which comprises the antibody according to claim 3 and a substance having anti-tumor activity and/or cell-killing activity.

### Claim 57 (depends on 55)

An antibody fragment-drug conjugate, which comprises the antibody fragment according to claim 55 and a substance having anti-tumor activity and/or cell-killing activity.

### Claim 58 (depends on 3)

A pharmaceutical composition, which comprises the antibody according to claim 3.

### Claim 59 (depends on 58)

The composition according to claim 58, which is used in the treatment of tumor.

### Claim 60 (depends on 59)

The composition according to claim 59, which does not cause weight reduction as a side effect.

### Claim 61 (depends on 58)

The composition according to claim 58, which is used in the diagnosis of tumor.

### Claim 62 (depends on 3)

A tumor therapeutic agent, which comprises the antibody according to claim 3.

### Claim 63 (depends on 3)

A tumor diagnostic agent, which comprises the antibody according to claim 3.

### Claim 64 (depends on 3)

A method for detecting a tumor, which comprises: allowing the antibody according to claim 3 to react with a sample collected from a living body; and then detecting a signal(s) of the reacted antibody.

### Claim 65 (depends on 3)

A kit for treating, diagnosing or detecting a tumor, which comprises the antibody according to claim 3.

### Claim 66 (depends on 3)

A polynucleotide encoding the antibody according to claim 3.

### Claim 67 (depends on 66)

A recombinant vector comprising the polynucleotide according to claim 66.

### Claim 68 (depends on 67)

A transformant comprising the recombinant vector according to claim 67.
